Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013
Nov 7, 2019 --ME-401 emerging as potential best-in-class PI3K delta inhibitor, with Phase 2 study intended to support accelerated approval with FDA in follicular lymphoma underway--
|
Oct 3, 2019 --MEI Investor and Analyst Event Webcast Tomorrow, October 4, 2019, at 8:00 a.m. Eastern Time--
|
Aug 28, 2019 - Clinical Progress Continues Across Oncology Portfolio, Highlighted by Expanding ME-401 Data Set Supporting Expedited Development Strategies and Additional Combination Therapy Opportunities -
|
Jun 1, 2019 - Statistically significant biologic anti-tumor activity demonstrated as measured by a reduction in Ki67 in patients treated with ME-344 compared to an increase in patients receiving placebo -
|
May 15, 2019 International Conference on Malignant Lymphoma (ICML) Selects ME-401 Abstract for Oral Presentation
|
